Aim immunotech inc. (HEB)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12Jun'12Mar'12Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Total revenues

45

-

61

29

-

240

38

33

56

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Clinical treatment programs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

45

36

76

-

36

36

42

-

-

-

45

36

-

35

41

Total Revenues

-

-

-

-

-

-

-

-

-

-

90

213

-

-

-

-

-

-

-

-

-

-

45

36

76

-

36

36

42

-

-

-

45

36

-

35

41

Clinical treatment programs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

23

47

36

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenues

-

-

-

-

-

-

-

-

-

-

-

-

84

16

22

15

39

27

23

47

36

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Costs and expenses:
Production costs

204

217

230

215

231

282

208

186

208

296

399

218

270

278

272

290

268

366

353

507

372

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Production

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

306

294

323

-

252

635

191

-

-

-

217

204

-

181

328

Research and development

898

1,437

1,190

1,096

928

987

1,595

1,341

855

814

787

1,106

1,391

1,863

1,342

900

1,002

957

1,968

2,439

2,674

2,438

1,894

2,330

2,326

1,533

2,173

2,318

2,336

-

-

-

1,750

1,624

-

1,808

1,694

General and administrative

2,268

1,484

1,846

1,942

1,767

1,632

1,273

1,733

1,563

1,733

1,556

1,619

1,664

1,960

1,634

1,639

2,448

1,547

1,685

2,002

1,913

1,847

2,174

2,497

2,539

1,759

2,070

1,817

2,077

-

-

-

1,635

1,456

-

1,738

1,788

Total costs and expenses

3,370

3,138

3,266

3,253

2,926

2,901

3,076

3,260

2,626

2,843

2,742

2,943

3,325

4,101

3,248

2,829

3,718

2,870

4,006

4,948

4,959

4,613

4,374

5,121

5,188

3,448

4,495

4,770

4,604

-

-

-

3,602

3,284

-

3,727

3,810

Operating loss

-3,325

-3,088

-3,205

-3,224

-2,926

-2,661

-3,038

-3,227

-2,570

-2,793

-2,652

-2,730

-3,241

-4,085

-3,226

-2,814

-3,679

-2,843

-3,983

-4,901

-4,923

-4,573

-4,329

-5,085

-5,112

-3,412

-4,459

-4,734

-4,562

-

-

-

-3,557

-3,248

-

-3,692

-3,769

Interest and other income

21

53

8

16

12

-13

-10

51

4

-

13

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment loss on investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

800

-

-

-

-

-

-

-

-

-

-

Interest expense and other finance costs

322

-111

193

99

246

249

59

55

139

69

51

19

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Convertible note valuation adjustment

-

-

-4

-74

-

-

-678

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and other income

-

-

-

-

-

-

-

-

-

-

-

21

26

-27

40

55

61

21

181

56

106

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Settlement of litigation/Insurance Claim

-

-

-

-260

-

-

-

-474

-

-

0

-

-

-

-190

-1,436

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Debt discount associated with extinguished debt

-

95

0

0

250

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of convertible note adjustment

-

-

-

-

90

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

3

3

-

4

5

5

-

-

-

9

6

-

5

0

Interest and other income/expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

130

131

153

-

89

354

181

-

-

-

212

317

-

443

93

Redeemable warrants valuation adjustment

182

-24

-446

-1,085

45

-338

-696

-362

231

-57

-1,438

-529

-393

-1,574

-103

0

0

-

0

-

-

-

0

-1

-

-

-

-

-

-

-

-

-

-

-

-

-

Settlement with vendor

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

0

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Litigation settlement net insurance proceeds

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain from sale of income tax operating losses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-1,374

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of building

-

-

-

-

-

0

0

0

223

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain (loss) on sale of marketable securities

-

-

-

7

-

-

11

-20

-

-

0

6

1

-

31

20

-107

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain from sale of income tax net operating losses and research credits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,561

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-3,808

-1,191

-2,948

-2,029

-3,365

-1,621

-3,078

-2,415

-2,713

-1,993

-1,252

-2,193

-2,821

-1,173

-2,862

-1,303

-2,164

-3,137

-3,803

-4,845

-3,445

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other comprehensive (loss) income:
Unrealized loss on marketable securities

4

-

-

-1

-

-

9

-33

-12

-8

11

18

12

-58

15

38

40

-252

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized loss on marketable securities

-

-

-

-6

-

-

-1

-

-

-10

0

-6

-1

-19

-31

0

107

556

-215

-137

111

-

-

-

-

-

197

-

-

-

-

-

-

-

-

-

-

Net comprehensive loss

-3,812

-

-2,948

-2,036

-3,365

-

-3,070

-2,448

-2,725

-2,011

-1,241

-2,181

-2,810

-1,250

-2,878

-1,265

-2,017

-2,833

-4,018

-4,982

-3,334

-

-

-

-

-

-

-

-

-

-

-

-3,269

-

-

-3,119

-

Gain from sale of income tax net operating losses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,126

-

0

0

686

-

-

-

-

-

-

-

-

Funds received from sale of income tax net operating losses (Note 15)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

-

Funds received from sale of income tax net operating losses (Note 13)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

Redeemable warrants valuation adjustment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

38

102

89

-

-

-

614

643

-

-584

2,260

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,202

-4,956

-3,836

-

-5,136

-4,283

-3,611

-

-

-

-2,740

-2,294

-

-3,838

-1,416

Unrealized gain (loss) on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-169

147

21

-

-

-1,005

45

-

-

-

-529

-

-

719

-

Reclassification adjustments for impairment losses included in net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

800

-

-

-

-

-

-

-

-

-

-

Reclassification adjustments for impairment losses included in net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

76

9

-

-

-

-

-

-

-

-

Net comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,371

-4,809

-3,815

-

-4,139

-5,364

-3,575

-

-

-

-

-

-

-

-

Basic and diluted loss per share

-0.22

2.49

-1.13

-1.07

-2.91

-4.45

-2.87

-2.38

-0.07

-0.06

-0.04

-0.08

-0.11

-0.05

-0.13

-0.06

-0.10

-0.55

-0.18

-0.02

-0.02

-1.04

-0.02

-0.03

-0.02

-0.02

-0.03

-0.03

-0.02

-

-

-

-0.02

-0.02

-

-0.02

-0.01

Weighted average shares outstanding, basic and diluted

17,490

8,911

2,603

1,898

1,156

-34,339

1,072

1,015

36,269

31,960

30,096

27,306

25,341

24,142

21,832

20,667

20,630

-391,631

20,564

236,149

213,634

-490,394

190,677

185,749

176,730

167,903

167,389

167,202

166,806

-

-

-

-

-

-

-

-

Stock issued for settlement of accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

48

-

-

Equity-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

105

54

36

-

-

27

-

-

Net comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,425

-2,786

-1,867

-

-

-407

-

-

Weighted average shares outstanding basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

135,496

135,375

-

134,869

133,107

United States [Member]
Clinical treatment programs

43

-

56

4

-

213

11

11

13

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Europe [Member]
Clinical treatment programs

2

-

5

25

-

27

27

22

43

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-